Introduction
Epilepsy and migraine-chronic disorders characterized by recurrent, episodic neurological dysfunction-are strongly associated co-morbid conditions. 1 Their pathophysiological relation were already ''long recognized'' at the end of 19th century 2 and a wealth of subsequent epidemiological evidence, summarized by Haut et al. 3 documented a bidirectional association of these families of neurological disorders, suggesting possible common pathophysiological mechanisms. 4 Similarly to epilepsy, the neurobiology of migraine is incompletely defined. 5 However, the concept of migraine as caused by a state of central neuronal hyperexcitability got consistent support from functional MRI evidence showing that the migraine aura-a visual hallucination/ illusion preceding the headache in $20% of migraine cases-is generated by a cortical spreading depression (CSD) event in the visual cortex. 6 CSD is a wave of deep transient suppression of brain bioelectric activity, propagating at $mm/min velocity. It can be elicited in the whole brain of anesthetized animals, as well as in rodent (e.g. Ref. 7) and human 8 neocortical slices in vitro by noxious maneuvers such as local application of KCl. Already since its discovery in 1944 by Leão, CSD was assumed to be associated with migraine aura.
Recently, it was shown that CSD activates trigeminal afferents that generate the headache upon causing inflammation in the painsensitive meninges, 9 so that CSD is the most probable primary event not only in (the less frequent) migraine with aura, but also in (the more frequent) migraine without aura. 5 The concept that brain hyperexcitability causes susceptibility for triggering migraine attacks provides a rational basis for using the antiepileptic drugs (AEDs) in migraine prophylaxis. 10 Several AEDs (valproate, topiramate, gabapentin, lamotrigine) are indeed used as migraine-preventive medication 4 and animal studies reported CSD suppression by migraine-prophylactic treatments. 11, 12 Brivaracetam (BRV; (2S)-2-[(4R)-2-oxo-4-propylpyrrolidinyl]-butanamide) is a newer pyrrolidone derivative, structurally related to levetiracetam (LEV). BRV displays a higher affinity than LEV to its binding site synaptic vesicle protein 2A (SV2A) 13 and has higher potency and efficacy than levetiracetam in animal models of epilepsy both in vitro and in vivo.
14 Currently, BRV is in development as an AED. 15 Here we report the results of assessing BRV in a recently described rat neocortical slice model of CSD 16 vs. LEV, taken as a comparator in view of its chemical kinship with BRV.
Materials and methods
The in vitro slice model used in this study was recently characterized in detail. 16 In brief, brain neocortical slices were prepared from male Sprague-Dawley rats (IFFA CREDO, Brussels, Belgium), between 5 and 7 weeks of age, according to standard procedures. The brain, quickly removed from the deeply anesthe- mm thick, were cut at the level of primary somato-sensory cortex with a Leica VT1000S vibratome (Leica, Germany), in refrigerated (<4 8C) and oxygenated (95% O 2 , 5% CO 2 ) ACSF. The slices were kept for 2 h at 32 8C in oxygenated ACSF. The procedures were approved by the local ethics committee for animal experimentation, in accordance with European Communities Council Directive 86/609/EEC, and all efforts were done to minimize the number of sacrificed animals and their pain. The recordings were done in interface chambers, at 32 8C, via two micropipette electrodes, placed on the cortical layers I-II of the slice, at points ''A'' and ''B'' spaced about 2.5 mm (Fig. 1, upper  left) . A stimulating bipolar Pt wire electrode was placed on the cortical layers V-VI, to elicit field potentials (recorded via the micropipettes ''A'' and ''B'') for checking slice responsiveness upon evoking AC field potentials, visualized on a Tektronix TDS oscilloscope. At %1.5 mm distance from the recording micropipette ''A'', also on the cortical layers I-II, was placed another micropipette, with the tip $10 mm, from which droplets of KCl, 3 M were delivered to induce CSD. The $nl-volume of KCl droplet was set via the open time ($s) of the electric microvalve of a homemade picoliter dispenser.
CSD episodes were acquired via a software which measures online the amplitude (Ampl) and duration at half-amplitude (D 1/2 ) of the characteristic DC field potentials (Fig. 1, upper right) . The DC field potentials from ''A'' and ''B'' were also recorded by a twochannel Gould TA240 recorder, as a paper trace synopsis of the whole experiment. Once the size of the KCl droplet inducing CSD at both ''A'' and ''B'' points was found, it was kept throughout the recording. Three CSD episodes were recorded, at 20-min intervals, with the slice perfused with standard ACSF, to confirm the stability and assess responsiveness uniformity among the groups of slices. The drug was added to the perfusion fluid 20 min after the third CSD episode, then, after other 20 min five subsequent CSD episodes were induced, at 20-min intervals, in the presence of the drug (protocol scheme in Fig. 1, bottom) .
BRV and LEV (both from UCB Pharma) have been dissolved in plain ACSF. Drug concentrations were chosen as reported active on neurons and brain slices in vitro: BRV-10 and 32 mM, 14,17 and LEV-32 and 100 mM. 18, 19 To unravel putative drug effects, the post-drug values of CSD Ampl and D 1/2 were normalized with respect to the pre-drug level (at the third CSD episode) in the same slice. The bar graphs in the section Results show mean AE S.E.M. of Ampl and D 1/2 of the CSD episodes elicited in parallel groups of drug-treated and control slices. The statistical significance of the differences between parallel groups of slices was assessed with one-tailed t-test.
Results
Application of identical droplets of KCl, 3 M at 20-min intervals consistently induced CSD events, recordable extracellularly as slow (up to 1-min duration) DC transients with a characteristic shape, appearing at the closer electrode ''A'', then-after a propagation latency-at the electrode ''B'' (Fig. 1, upper right) .
As the CSDs successively elicited at 20-min intervals present a facilitation tendency, better expressed on the duration, 16 the graphs in Figs. 2 and 3 show the normalized Ampl and D 1/2 of the first and the last post-drug CSD episodes, respectively termed ''Early'' and ''Late''. The data in Fig. 2 show that BRV, 10 and 32 mM reduced the Ampl and transiently the D 1/2 of the CSD episodes, recorded at both recording points. However, a concentration-dependence was expressed only partially. In contrast to BRV, LEV did not modify either Ampl or D 1/2 of CSDs, at any of the two recording points (Fig. 3) .
Discussion
The proven relevance of the CSD phenomenon in migraine pathology 5, 11, 12 entails inferring that the noteworthy reductions of both amplitude and duration of CSDs, produced by BRV in this model (Fig. 2 ) might conceivably express a migraine-prophylactic potential of this drug. Migraine is frequent in patients with epilepsy 1, 21 and it was shown that migraine with aura entails in children a substantial increased risk to develop epilepsy. 22 Consequently, confirming a possible anti-migraine activity of a forthcoming AED deserves further investigation, in view of the potential relevance for both migraine and epilepsy therapy. The CSD-depressing effect of BRV herein reported is in principle reminiscent of the migraine-preventing capabilities of other AEDs, such as gabapentin, lamotrigine, topiramate and valproate, though the results of various clinical studies assessing those AEDs in migraine prophylaxis are sometimes conflicting and the prophylactic treatment of migraine hardly reaches 50% efficacy (for review, see Ref. 23) . The difference between the partial anti-CSD activity of BRV (Fig. 2) and the full CSD-blocking effect of the NMDA antagonist MK-801 in our model 16 suggests that the targets of BRV might be less important for CSD elicitation than the NMDA channel. A similar conclusion was reached years ago in the case of other AEDs. 24 A point worth noticing, however, is that acute drug application upon perfusion on slices from untreated animals, as in the current in vitro model, is not meant to mimic the chronic treatment underlying a migraine-preventing activity. Thus, even a transient and partial effect detected upon such short-term exposure might, nevertheless, be a fair hint of putative migraine-preventing activity. This conjecture is supported by the recent report that several drugs widely prescribed for migraine prophylaxis, including the AEDs topiramate and valproate, inhibited CSD in anesthetized rats in vivo when chronically administered, longer treatments producing stronger CSD suppression, whereas the acute treatment was ineffective. 12 LEV, assessed as a comparator only in view of its chemical kinship with BRV, was devoid of effect on CSD in this model. The lack of anti-CSD effect of LEV is congruent with the absence of other pathologies than epilepsy from the registered indications of this AED 25 and also points to some mechanistic difference between BRV and LEV, beyond their different SV2A affinities. Indeed, BRV has been reported to inhibit neuronal Na + channels, 17 at difference from LEV that does not act on neuronal Na + current. 26 Therefore, it seems plausible to tentatively infer that the excitability dampening effect of Na + channels inhibition by BRV not only contributes to the anticonvulsant effects of this drug, well expressed in vivo and in vitro, 14 but also might entail a migraine-preventive activity.
Confirming this conjecture is, however, hampered by the scarcity of the current knowledge of the mode of action of most drugs used in migraine prophylaxis, and it goes beyond the scope of this exploratory study. In summary, this study has shown that the novel AED candidate BRV reduces CSD episodes regularly elicited in rat neocortical slices in vitro, an effect that might suggest an anti-migraine potentiality of this compound, deserving further investigation.
